News

Filter

Current filters:

None

82 to 91 of 97551 results

New phase of MAb biosimilars opportunities in Japan

New phase of MAb biosimilars opportunities in Japan

21-01-2015

The launch of Remicade (infliximab, from Johnson & Johnson) biosimilar in December 2014 in the Japan…

BiosimilarserythropoietinGenericsJapanMarkets & MarketingRegulationRemicade

Bristol-Myers to promote Caforio to CEO post; other appointments

Bristol-Myers to promote Caforio to CEO post; other appointments

21-01-2015

US pharma major Bristol-Myers Squibb yesterday announced a number of leadership changes approved by its…

BoardroomBristol-Myers SquibbManagementPharmaceuticalUSA

Novo Nordisk's Victoza granted label extension in the UK

Novo Nordisk's Victoza granted label extension in the UK

20-01-2015

A license extension has been granted in the UK for Victoza (liraglutide) from Danish insulin giant Novo…

Nephrology and HepatologyNovo NordiskPharmaceuticalRegulationUKVictoza

Johnson & Johnson beats profit forecasts, but group sales shy

Johnson & Johnson beats profit forecasts, but group sales shy

20-01-2015

US health care giant Johnson & Johnson has reported financial results for the fourth-quarter and full-year…

FinancialJohnson and JohnsonPharmaceutical

Strides Arcolab to make and distribute Gilead’s TAF

20-01-2015

Indian drugmaker Strides Arcolab Limited has entered into a licensing agreement with US biotech major…

Anti-viralsGenericsGilead SciencesLicensingProductionStrides Arcolabtenofovir alafenamide

Ariad gets positive final EC decision on Iclusig

20-01-2015

USA-based Ariad Pharmaceuticals today revealed that the European Commission has endorsed the final opinion…

Ariad PharmaceuticalsEuropeIclusigOncologyPharmaceuticalRegulation

FDA removes hold on CytRx's aldoxorubicin Phase III trials

FDA removes hold on CytRx's aldoxorubicin Phase III trials

20-01-2015

The US Food and Drug Administration has removed the partial clinical hold on biopharma oncology company…

aldoxorubicinBiotechnologyCytRxOncologyRegulationResearchUSA

Tiziana licenses potential cancer therapy milciclib from Nerviano

Tiziana licenses potential cancer therapy milciclib from Nerviano

20-01-2015

Oncology and immunology specialist Tiziana Life Sciences has exclusively licensed milciclib from Nerviano…

LicensingmilciclibNerviano Medical SciencesOncologyPharmaceuticalResearchTiziana

82 to 91 of 97551 results

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top